Cardiology Research Analysis
Across 2025-Q3, cardiology research coalesced around physiology-first care, scalable AI-enabled diagnostics, and mechanistically grounded precision therapeutics. A long-term randomized trial established PET-derived coronary flow capacity as a foundation for selective revascularization alongside intensified lifestyle and medical therapy. Parallel AI innovations delivered dynamic, point-of-care bleeding risk for PCI and wearable noninvasive estimation of pulmonary capillary wedge pressure. Cardiom
Summary
Across 2025-Q3, cardiology research coalesced around physiology-first care, scalable AI-enabled diagnostics, and mechanistically grounded precision therapeutics. A long-term randomized trial established PET-derived coronary flow capacity as a foundation for selective revascularization alongside intensified lifestyle and medical therapy. Parallel AI innovations delivered dynamic, point-of-care bleeding risk for PCI and wearable noninvasive estimation of pulmonary capillary wedge pressure. Cardiometabolic prevention advanced through upfront finerenone plus SGLT2 inhibition, robust weight loss with a GLP-1/glucagon dual agonist, and absolute-effect estimates for GLP-1 receptor agonists. Mechanistic work clarified TNFR2-driven vascular toxicity of ponatinib and introduced non-sarcomeric tubulin tyrosination as a hypertrophic cardiomyopathy axis, while an 87‑CpG methylation score improved macrovascular risk stratification in type 2 diabetes.
Selected Articles
1. Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial.
A randomized trial (n=1,028) showed that a comprehensive program combining intensive lifestyle, goal-directed medical therapy, and PET-derived coronary flow capacity to triage revascularization reduced 11-year all-cause mortality, death or MI, late revascularization, and MACE compared with usual care.
Impact: Provides long-term randomized evidence that physiology-guided, selective revascularization within comprehensive care improves hard outcomes in chronic CAD.
Clinical Implications: Supports integrating PET-CFC into care pathways to prioritize aggressive lifestyle and medical therapy, reserving revascularization for physiologically severe disease.
Key Findings
- Reduced 11-year all-cause mortality and death or MI with the comprehensive program.
- Lower late revascularization and MACE; early revascularization remained uncommon.
- Combines lifestyle intensification, goal-directed therapy, close follow-up, and PET-CFC–guided triage.
2. Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.
Preclinical models show ponatinib uniquely drives endothelial TNFR upregulation, leukocyte/platelet activation, plaque inflammation, and ischemic deaths, while asciminib lacks these effects; TNFR pharmacologic blockade or TNFR2 knockdown abrogates toxicity.
Impact: Clarifies a targetable TNFR2-driven mechanism for TKI-associated arterial events, reshaping cardio-oncology risk frameworks and therapeutic hypotheses.
Clinical Implications: Prefer Abl inhibitors without TNFR2-mediated vascular activation in high-risk patients; intensify CV surveillance for ponatinib users; consider TNF/TNFR modulation in trials.
Key Findings
- Ponatinib rapidly increases endothelial TNFR expression and adhesion molecules.
- In vivo, it augments leukocyte rolling/adhesion, platelet activation, and plaque inflammation, accelerating MI and stroke.
- TNFR inhibition or TNFR2 knockdown neutralizes endothelial activation and ischemic events; asciminib lacks these effects.
3. Epigenetic biomarkers predict macrovascular events in individuals with type 2 diabetes.
An 87‑CpG methylation risk score predicted incident macrovascular events with high discrimination and reclassification in T2D, outperforming established clinical and polygenic tools and validating across external cohorts.
Impact: Demonstrates a scalable, blood-based test that materially improves cardiovascular risk stratification in T2D and aligns with precision prevention.
Clinical Implications: May guide intensity of lipid-lowering, BP control, antithrombotic therapy, and surveillance after implementation and health-economic validation.
Key Findings
- 87‑CpG methylation score achieved AUC around 0.81–0.84 combined with clinical factors.
- Outperformed SCORE2-Diabetes, UKPDS, Framingham, and polygenic scores with high NPV and NRI gains.
- Validated across independent cohorts with tissue-level biological plausibility.
4. Noninvasive Pulmonary Capillary Wedge Pressure Estimation in Heart Failure Patients With the Use of Wearable Sensing and AI.
A multicenter prospective diagnostic study (n=310 HFrEF) showed that a multimodal wearable (ECG, seismocardiography, PPG) with machine learning estimated PCWP against right heart catheterization with an error of 1.04 ± 5.57 mmHg and stable performance across demographics.
Impact: Shows clinically acceptable, scalable accuracy for noninvasive hemodynamics, enabling hemodynamics-guided HF care without implantables.
Clinical Implications: If validated ambulatory, could guide therapy titration and early decompensation detection, reducing hospitalizations and standardizing follow-up.
Key Findings
- Multimodal wearable signals with ML estimated PCWP with low bias versus RHC.
- Performance was consistent across sex, race/ethnicity, and BMI categories.
- Prospective multicenter design with blinded adjudication supported rigor.
5. Tubulin tyrosine ligase variant perturbs microtubule tyrosination, causing hypertrophy in patient-specific and CRISPR gene-edited iPSC-cardiomyocytes.
Patient-derived and CRISPR-edited iPSC cardiomyocytes link a pathogenic TTL p.G219S variant to reduced tubulin tyrosination, detyrosinated tubulin accumulation, disrupted redox signaling, and cardiomyocyte hypertrophy, nominating a non-sarcomeric HCM mechanism.
Impact: Expands HCM genetics beyond sarcomeric mutations and identifies the tubulin tyrosination cycle as a druggable pathway.
Clinical Implications: Supports broader genetic testing and motivates therapies restoring tubulin tyrosination or redox homeostasis.
Key Findings
- Pathogenic TTL p.G219S identified in HCM.
- Reduced TTL activity leads to detyrosinated tubulin accumulation.
- Redox signaling perturbation induces hypertrophy in patient-specific and edited iPSC-CMs.
6. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
CONFIDENCE showed that initial combination of finerenone plus empagliflozin produced a 29–32% greater reduction in urinary albumin-to-creatinine ratio at 180 days versus either agent alone in CKD with T2D, without new safety signals.
Impact: High-quality randomized evidence supporting simultaneous MR antagonism and SGLT2 inhibition to enhance antiproteinuric effects, potentially altering therapy sequencing.
Clinical Implications: Supports earlier finerenone plus SGLT2 inhibitor initiation in CKD with T2D, with monitoring for hyperkalemia and renal function while awaiting hard-outcome data.
Key Findings
- Greater UACR reduction vs finerenone alone (LS mean ratio 0.71).
- Greater UACR reduction vs empagliflozin alone (LS mean ratio 0.68).
- No unexpected safety signals.
7. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
A phase-3, double-blind randomized trial (n=610) showed once-weekly mazdutide 4 mg and 6 mg produced −11.0% and −14.0% mean weight reductions at 48 weeks with broad cardiometabolic improvements and mainly mild-to-moderate GI adverse events.
Impact: Demonstrates robust weight loss with a GLP‑1/glucagon dual agonist and cardiometabolic benefits that may translate into long-term CV risk reduction.
Clinical Implications: Expands options for obesity management within cardiometabolic care; clinicians should monitor GI tolerability and await CV outcome data.
Key Findings
- Mean weight change −11.0% (4 mg) and −14.0% (6 mg) at 48 weeks.
- High proportions achieved ≥5% and ≥15% weight loss with metabolic improvements.
- Adverse events primarily mild-to-moderate GI symptoms with low discontinuation.
8. Towards a dynamic model to estimate evolving risk of major bleeding after percutaneous coronary intervention.
Using 2.87 million index PCIs from the NCDR CathPCI registry, tree-based machine learning models updated bleeding risk at procedural decision points, improving AUROC to 0.845 and reclassifying small subgroups missed by static models.
Impact: Operationalizes large-scale, point-of-care dynamic risk prediction for PCI with measurable gains over static tools.
Clinical Implications: Embed dynamic risk updates to inform access strategy, antithrombotic choices, and closure device selection; prospectively monitor calibration and clinician uptake.
Key Findings
- AUROC improved from 0.812 to 0.845 with all variables.
- Identified small reclassified high-risk groups with markedly higher observed bleeding.
- Aligned model stages with procedural decision points for real-time guidance.
9. Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation.
Mechanistic translational research shows SIRT1 directly binds and deacetylates PCSK9 (Lys243/Lys421/Lys506), increasing hepatic LDLR, lowering LDL-C, and reducing plaque in ApoE−/− mice; higher plasma SIRT1 in ACS patients correlated with lower PCSK9 and fewer MACE.
Impact: Identifies an epigenetically modifiable SIRT1–PCSK9 axis linking deacetylation to LDLR preservation and atherosclerosis modulation.
Clinical Implications: Supports development of SIRT1 activators or acetylation-modulating therapies complementing statins/PCSK9 inhibition; plasma SIRT1 may serve as a prognostic biomarker pending trials.
Key Findings
- Recombinant SIRT1 increased hepatic LDLR and reduced LDL-C and plaque in ApoE−/− mice.
- SIRT1 deacetylated PCSK9 at Lys243/Lys421/Lys506, decreasing PCSK9 activity.
- Higher plasma SIRT1 in ACS patients correlated with lower PCSK9 and fewer MACE.
10. Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety.
A meta-analysis of 25 RCTs (109,846 patients) showed GLP-1 receptor agonists reduce MI, CV mortality, MACE, and stroke with quantifiable absolute benefits (e.g., MACE NNT 67) and increased GI adverse events (NNTH 9).
Impact: Translates relative risks into absolute-effect estimates across broad populations, informing individualized prevention and policy.
Clinical Implications: Supports broader GLP-1RA use for ASCVD risk reduction, especially at higher BMI, with shared decision-making on GI tolerability.
Key Findings
- Reduced MI (RR 0.86; NNT 207) and CV mortality (RR 0.87; NNT 170).
- Reduced MACE (RR 0.87; NNT 67) and stroke (RR 0.88; NNT 335).
- Greater MI risk reduction at higher BMI; increased GI adverse events (RR 1.55; NNTH 9).